Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™ based in Cambridge, Mass, has appointed Elizabeth (Betsy) Nabel to its Board of Directors. Nable is the President of Harvard-affiliated Brigham and Women’s Health Care (BWHC) and a Professor of Medicine at Harvard Medical School.
“Nable’s pioneering expertise in translational research is well-aligned with our rapid progress of our mRNA therapeutics from scientific concept to real-world medical solutions for a broad spectrum of diseases and unmet patient needs,” said Stéphane Bancel, Moderna’s CEO.
“There is great potential for mRNA therapeutics to transform the future of medicine and expand the boundaries of science to improve the lives of patients,” commented Nable.
Nable previously served as the Director of the National Institute of Health’s National Heart, Lung and Blood Institute (NHLBI) where she leveraged the $3 billion research portfolio to establish pioneering scientific programs in genomics, stem cells and translational research. A long-time champion for global health, while at NHLBI, Nabel established Centers of Excellence in developing countries to combat cardiovascular and lung diseases. At BWHC she helped create a national teaching hospital in Haiti and is advancing training for clinicians in under-resourced countries. An accomplished physician-scientist, Nabel’s work on the molecular genetics of cardiovascular diseases has yielded 17 patents and resulted in more than 250 scientific publications.
Moderna is privately held and currently has strategic agreements with AstraZeneca, Alexion Pharmaceuticals and Merck. The company currently plans to develop and commercialize its innovative mRNA drugs through a combination of strategic relationships as well as newly formed ventures, including Onkaido Therapeutics LLC, focused on oncology drug development, Valera LLC, focused on infectious diseases, Elpidera LLC, focused on rare diseases, and Caperna LLC, focused on personalized cancer vaccines.
Moderna Therapeutics’ board of directors currently consists of Noubar Afeyan, Lee Babiss, Stéphane Bancel, Robert Carpenter, Peter Barton Hutt, Robert Langer, Theo Melas-Kyriazi, John Mendlein, Elizabeth Nabel and Henri A. Termeer.